Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A single-cell atlas of CD19 chimeric antigen receptor T cells.
Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. Li X, et al. Among authors: green mr. Cancer Cell. 2023 Nov 13;41(11):1835-1837. doi: 10.1016/j.ccell.2023.08.015. Epub 2023 Sep 21. Cancer Cell. 2023. PMID: 37738975
Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Dang M, et al. Among authors: green mr. Cancer Cell. 2023 Jun 12;41(6):1032-1047.e4. doi: 10.1016/j.ccell.2023.05.007. Cancer Cell. 2023. PMID: 37311413
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. Strati P, et al. Among authors: green mr. Blood Adv. 2023 Nov 14;7(21):6785-6789. doi: 10.1182/bloodadvances.2023010653. Blood Adv. 2023. PMID: 37389847 Free PMC article. Clinical Trial. No abstract available.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Among authors: green mr. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. Deng Q, et al. Among authors: green mr. Cancer Cell. 2024 Apr 8;42(4):605-622.e11. doi: 10.1016/j.ccell.2024.02.011. Epub 2024 Mar 7. Cancer Cell. 2024. PMID: 38458188 Free article.
Activated B cells suppress T-cell function through metabolic competition.
Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Imahashi N, et al. J Immunother Cancer. 2022 Dec;10(12):e005644. doi: 10.1136/jitc-2022-005644. J Immunother Cancer. 2022. PMID: 36543374 Free PMC article.
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. Barisic D, et al. Among authors: green mr. Cancer Cell. 2024 Apr 8;42(4):720-722. doi: 10.1016/j.ccell.2024.03.012. Cancer Cell. 2024. PMID: 38593783 No abstract available.
Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
Mishra AK, Ye T, Banday S, Thakare RP, Su CT, Pham NNH, Ali A, Kulshreshtha A, Chowdhury SR, Simone TM, Hu K, Zhu LJ, Eisenhaber B, Deibler SK, Simin K, Thompson PR, Kelliher MA, Eisenhaber F, Malonia SK, Green MR. Mishra AK, et al. Among authors: green mr. Cell Rep. 2024 Apr 23;43(4):114041. doi: 10.1016/j.celrep.2024.114041. Epub 2024 Apr 3. Cell Rep. 2024. PMID: 38573857 Free article.
Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma.
Plotnik JP, Richardson AE, Yang H, Rojas E, Bontcheva V, Dowell C, Parsons S, Wilson A, Ravanmehr V, Will C, Jung P, Zhu H, Partha SK, Panchal SC, Mali RS, Kohlhapp FJ, McClure RA, Ramathal CY, George MD, Jhala M, Elsen NL, Qiu W, Judge RA, Pan C, Mastracchio A, Henderson J, Meulbroek JA, Green MR, Pappano WN. Plotnik JP, et al. Among authors: green mr. Mol Cancer Ther. 2024 Mar 20. doi: 10.1158/1535-7163.MCT-23-0518. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38507740
892 results